'Rogaine' in a Pill? Oral Minoxidil Aces Major Hair Loss Trial
Gizmodo • • business
Key Points:
- Veradermics announced that its oral minoxidil formulation, VDPHL01, successfully passed a Phase II/III clinical trial, showing significant hair growth in men with pattern hair loss compared to placebo.
- VDPHL01 is an extended-release oral drug designed to maintain effective drug levels for hair growth while minimizing cardiovascular side effects commonly associated with oral minoxidil.
- In the trial involving over 500 men, 79% of the single-dose group and 86% of the twice-daily group experienced significant hair growth, with safety profiles comparable to placebo and minimal adverse effects.
- If approved, VDPHL01 would be the first new oral treatment for pattern baldness in nearly 30 years, offering an alternative to topical minoxidil and finasteride, potentially transforming hair loss treatment.
- Veradermics plans to pursue regulatory approval, with experts expressing optimism that the drug could become a widely used, non-hormonal option for millions affected by androgenetic alopecia.
